A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate how effective and safe the study drug known as
 ixekizumab is in participants with active psoriatic arthritis.
Inclusion Criteria:

 -  Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6
 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria

 -  Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints

 -  Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)

 -  Men must agree to use a reliable method of birth control or remain abstinent during
 the study

 -  Women must agree to use reliable birth control or remain abstinent during the study
 and for at least 12 weeks after stopping treatment

 -  Have been treated with 1 or more conventional disease-modifying antirheumatic drugs
 (cDMARDs)

 -  Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor
 (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due
 to either an inadequate response (based on a minimum of 12 weeks on therapy) or
 documented intolerance.

 Exclusion Criteria:

 -  Current use of biologic agents for treatment of Ps or PsA

 -  Inadequate response to greater than 2 biologic DMARDs

 -  Current use of more than one cDMARDs

 -  Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other
 than PsA

 -  Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal
 antibody (MAb) therapy

 -  Serious disorder or illness other than psoriatic arthritis

 -  Serious infection within the last 3 months

 -  Breastfeeding or nursing (lactating) women